Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 14/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 14/20 | 0.38 |
| ▸ | PDK3 | Q15120 | 14/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 14/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.35 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.35 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.35 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3896419 | 1.00 | PDK1 (0.38) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL3897596 | 1.00 | PDK1 (0.38) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL13792298 | 0.78 | — | — | |
| SCHEMBL13967284 | 0.75 | ALDH1A1 (0.37) | — | |
| SCHEMBL569205 | 0.75 | ALDH1A1 (0.53) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL568924 | 0.75 | ALDH1A1 (0.53) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL568925 | 0.75 | ALDH1A1 (0.53) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL622355 | 0.74 | — | — | |
| SCHEMBL435447 | 0.74 | — | — | |
| SCHEMBL9722984 | 0.73 | LMNA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | claimed |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2024-02-22 | — | — | US | claimed |
| CN-113891744-A | Pyridine and pyrazine derivatives for the treatment of CF, COPD and bronchiectasis | 诺华股份有限公司 | 2022-01-04 | — | — | CN | claimed |
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | claimed |
| WO-2020250116-A1 | PYRIDINE AND PYRAZINE DERIVATIVE FOR THE TREATMENT OF CF, COPD, AND BRONCHIECTASIS | NOVARTIS AG (CH) | 2020-12-17 | — | — | WO | claimed |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2020-12-10 | — | — | US | claimed |
| US-10117858-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2018-11-06 | — | — | US | claimed |
| US-RE46757-E1 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2018-03-20 | — | — | US | claimed |
| EP-2845593-B1 | Pyridine and pyrazine derivative for the treatment of chronic obstructive pulmonary disease | NOVARTIS AG (CH) | 2017-01-25 | — | — | EP | claimed |
| US-9365552-B2 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | claimed |
| EP-1372630-A4 | AGENT FOR THE TREATMENT OF OVERACTIVE BLADDER | KYOWA HAKKO KOGYO KK (JP) | 2005-03-23 | — | — | EP | claimed |
| US-6773910-B1 | VIA MICROORGANISM (ARTHROBACTER, BACILLUS, KLEBSIELLA, AND PSEUDOMONAS) WHICH UTILIZES PROPIONIC ACID AMIDE COMPOUND AS SOLE NITROGEN SOURCE | LONZA AG (CH) | 2004-08-10 | — | — | US | claimed |
| EP-1372639-A2 | AGENT FOR THE TREATMENT OF BLADDER IRRITATIVE SYMPTOMS ACCOMPANIED BY BENIGN PROSTATIC HYPERPLASIA | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-01-02 | — | — | EP | claimed |
| EP-1372630-A2 | AGENT FOR THE TREATMENT OF OVERACTIVE BLADDER | Kyowa Hakko Kogyo Co., Ltd (JP) | 2004-01-02 | — | — | EP | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| US-20030087402-A1 | Process for the preparation of (S) - or (R) -3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid | BRIEDEN WALTER (CH) | 2003-05-08 | — | — | US | claimed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | claimed |
| WO-2002078523-A2 | AGENT FOR THE TREATMENT OF OVERACTIVE BLADDER | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-10-10 | — | — | WO | claimed |
| WO-2002078633-A2 | AGENT FOR THE TREATMENT OF BLADDER IRRITATIVE SYMPTOMS ACCOMPANIED BY BENIGN PROSTATIC HYPERPLASIA | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-10-10 | — | — | WO | claimed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | PDK1 475/4885PDK2 1141/4885PDK3 1447/4885 |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | PDK1 332/4885PDK2 767/4885PDK3 853/4885 |
| US-10117858-B2 | Pyridine and pyrazine derivative for the treatment of CF | CFTR, OPRK1, OPRD1 | PDK1 475/4885PDK2 1141/4885PDK3 1447/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | PDK1 305/4885PDK2 908/4885PDK3 1086/4885 |
| US-20240058315-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | PDK1 332/4885PDK2 767/4885PDK3 853/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | PDK1 4120/4885PDK2 3798/4885PDK3 3558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.